Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8973988 | 0.98 | KDM4E (0.59) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL396870 | 0.84 | ALDH1A1 (0.80) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL8974039 | 0.84 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL8974038 | 0.84 | RXFP1 (0.48) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL3023711 | 0.81 | MAPT (0.61) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL3037639 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL8974059 | 0.81 | RXFP1 (0.42) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL2549273 | 0.80 | PIK3CG (0.58) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL2318474 | 0.79 | KDM4E (0.67) | KDM4EALDH1A1LMNATDP1MAPT | |
| SCHEMBL3038241 | 0.79 | KDM4E (0.57) | KDM4EALDH1A1LMNATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378208-B2 | N-substituted oseltamivir derivatives with antimicrobial activity | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20250051638-A1 | POWDERED FLUOROCHROME COMPOSITION, RESIN COMPOSITION, MOLDED ARTICLE, AND METHOD FOR PRODUCING POWDERED FLUOROCHROME COMPOSITION | DIC CORPORATION (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20250011292-A1 | NOVEL RHODANINE DERIVATIVES AND USES THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| EP-4415704-A1 | NOVEL RHODANINE DERIVATIVES AND USES THEREOF | Georgia State University Research Foundation, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118434822-A | Powdery pigment composition, method for producing powdery pigment composition, resin composition, and molded article | DIC株式会社 | 2024-08-02 | — | — | CN | disclosed |
| WO-2023064368-A1 | NOVEL RHODANINE DERIVATIVES AND USES THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20220306592-A1 | N-SUBSTITUTED OSELTAMIVIR DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-09-29 | — | — | US | disclosed |
| CN-114286817-A | N-substituted oseltamivir derivatives having antimicrobial activity | 香港理工大学 | 2022-04-05 | — | — | CN | disclosed |
| EP-3059288-B1 | RESIN COMPOSITION AND MOLDED ARTICLE | DAINIPPON INK & CHEMICALS (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-20210030895-A1 | RESIN COMPOSITION AND MOLDED ARTICLE | DIC CORPORATION (JP) | 2021-02-04 | — | — | US | disclosed |
| WO-2008005651-A2 | CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS | DECODE CHEMISTRY, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007121432-A2 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2007-10-18 | — | — | US | disclosed |
| EP-1697335-A1 | FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063727-A1 | FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2005-07-14 | — | — | WO | disclosed |
| EP-0039892-B1 | SUBSTITUTED PHENYL ETHERS | CIBA-GEIGY AG (CH) | 1986-12-30 | — | — | EP | disclosed |
| US-4559354-A | ADRENERGIC BLOCKING AGENTS AND STIMULANTS; CARDIOTONIC, ANTIARRHYTHMIA AND INOTROPIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0039892-A1 | Substituted phenyl ethers | CIBA-GEIGY AG (CH) | 1981-11-18 | — | — | EP | disclosed |
| US-3946049-A | 5-PHENYL-2-FURAMIDOXIMES | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306592-A1 | N-SUBSTITUTED OSELTAMIVIR DERIVATIVES WITH ANTIMICROBIAL ACTIVITY | CTSA, MAVS, PNP | KDM4E 4431/4885ALDH1A1 1013/4885LMNA 2317/4885 |
| US-20210030895-A1 | RESIN COMPOSITION AND MOLDED ARTICLE | IK, CBR3, RER1 | KDM4E 1200/4885ALDH1A1 643/4885LMNA 1854/4885 |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | PPARD, PPARG, PPARA | KDM4E 4792/4885ALDH1A1 670/4885LMNA 2040/4885 |
| US-12378208-B2 | N-substituted oseltamivir derivatives with antimicrobial activity | CTSA, MAVS, PNP | KDM4E 4431/4885ALDH1A1 1013/4885LMNA 2317/4885 |
| US-20250011292-A1 | NOVEL RHODANINE DERIVATIVES AND USES THEREOF | ACE2, RARG, ALAD | KDM4E 4281/4885ALDH1A1 955/4885LMNA 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.